Telix share price sinks 9% despite stellar half-year growth

This radiopharmaceuticals company delivered strong growth during the first half.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the move on Friday morning.

At the time of writing, the ASX 200 healthcare stock is down 9% to $18.04.

This follows the release of its half-year results after the market close yesterday.

Telix share price sinks on half year results

  • Total group revenue up 65% to $364 million
  • Gross margin up to 66% from 63%
  • Adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) up 66% to $57.5 million
  • Net profit after tax of $29.7 million (up from a loss of $14.3 million)
  • FY 2024 guidance reaffirmed

What happened during the half?

For the six months ended 30 June, the ASX 200 healthcare stock reported a 65% increase in revenue to $364 million. This reflects continued growth in sales of its prostate cancer imaging agent Illuccix in the United States, which is now in its second full year of commercial sales.

Telix's gross margin improved to 66% (from 63%) due to the stable selling price of Illuccix and disciplined cost control.

This ultimately led to the company delivering a half-year net profit after tax of $29.7 million. This compares favourably to a loss of $14.3 million in the prior corresponding period.

Management commentary

The ASX 200 healthcare stock's managing director and CEO, Dr Christian Behrenbruch, was pleased with the results. He said:

Telix continues to grow revenue from Illuccix, increase gross profit margin and manage costs effectively, while investing for future growth. Our achievements in the first half of 2024 have created value for shareholders and positioned the Company for success on multiple fronts.

Building on our commercial success with Illuccix, we are focused on expanding the near-term opportunity in precision medicine diagnostics with three new products planned for launch in 2025, subject to regulatory approval.

At the same time, new efficacy data from the ProstACT SELECT trial has reinforced the therapeutic potential of TLX591 – our Phase III asset for prostate cancer therapy, while we have a number of additional significant clinical milestones ahead across our therapeutic pipeline.

Outlook

Failing to give the Telix share price a lift today is news that management has reaffirmed its guidance for FY 2024.

It continues to guide to full-year 2024 revenue of US$490 million to US$510 million (A$745 million to A$776 million at current exchange rates). This represents a 48% to 54% increase on what was recorded in FY 2023.

Telix also confirmed that its previously advised guidance for research and development expenditure remains unchanged.

Dr Behrenbruch concludes:

We believe the radiopharmaceutical sector is at an inflection point and Telix has the proven commercial ability, clinical experience and balance sheet strength to advance our leading-edge theranostic pipeline.

With a proven revenue stream and a clear path to future business growth, Telix is positioned at the vanguard of this fast-growing field.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Happy shopper at a clothes shop.
Earnings Results

Why did Myer shares just rocket 9%?

Investors are piling into Myer shares on Friday. But why?

Read more »

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Up 78% since April, why is the Webjet share price taking off again today?

Webjet shares have soared 78% since 4 April and are lifting off again today. But why?

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Industrials Shares

Guess which ASX 200 stock is crashing 24% on results day

Investors were not impressed with this result. But why?

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Technology Shares

ASX 300 tech stock charges 7% higher to record high on stellar results

This tech stock delivered another impressive result this morning.

Read more »

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Consumer Staples & Discretionary Shares

Why is the Kogan share price crashing 12%?

Profits are down at this ecommerce company during the second half.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Resources Shares

Guess which ASX 200 mining stock is sinking 7% following its quarterly update

Let's see how this miner performed during the third quarter.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

Up 50% in a year, are Xero shares a buy after Thursday's earnings results?

ASX investors reacted positively to Xero’s full-year earnings results on Thursday. Now what?

Read more »